Full-Time

Neuroscience Therapeutic Sales Specialist

Updated on 9/4/2026

Compass Pathways

Compass Pathways

201-500 employees

Develops psilocybin-based therapies for TRD

Compensation Overview

$165k - $195k/yr

+ Discretionary bonus + Equity

No H1B Sponsorship

Dayton, OH, USA + 1 more

More locations: Cincinnati, OH, USA

In Person

Field-based role with travel of up to 70%, depending on geography.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales

Get referred to Compass Pathways

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • Five to eight or more years of pharmaceutical or biotechnology sales experience is required, preferably in specialty or complex therapeutic areas.
  • Demonstrated success in launching novel therapies or operating in pre-launch environments is required.
  • Strong clinical acumen and the ability to communicate complex scientific concepts clearly and compellingly are required.
  • A proven track record of building trust-based relationships with healthcare providers is required.
  • The ability to work effectively across cross-functional teams is required.
  • Strong business acumen, territory management, and organizational skills are required.
Responsibilities
  • Execute territory-level commercial strategy to support the successful launch and uptake of the company’s innovative mental health therapy.
  • Develop and maintain strategic relationships with psychiatrists, treatment centers, behavioral health systems, and other key stakeholders.
  • Deliver scientifically accurate, compliant, and compelling product and disease-state education to healthcare providers.
  • Identify appropriate patients and support healthcare providers in understanding patient selection and referral pathways.
  • Collaborate with certified treatment sites to support onboarding, readiness, and optimization of treatment delivery workflows.
  • Navigate site-of-care dynamics, including scheduling, patient flow, and operational considerations unique to the treatment model.
  • Partner cross-functionally with Medical Affairs, Market Access, Patient Support, and Commercial Operations to ensure coordinated execution.
  • Support patient access by understanding reimbursement pathways, assisting providers with access-related challenges, and connecting them to relevant resources.
  • Gather and communicate actionable field insights to inform brand strategy, patient journey optimization, and launch execution.
  • Manage territory business planning, including account prioritization, call planning, and performance tracking.
  • Demonstrate ethical, compliant, and patient-centric behaviors in all engagements.
  • Contribute to collaboration, accountability, and continuous learning within the broader sales organization.
Desired Qualifications
  • An advanced degree is preferred.
  • Experience in psychiatry, central nervous system, or behavioral health markets is preferred.
  • Experience with medical and pharmacy benefit reimbursement is preferred.
  • Experience with buy-and-bill and site-of-care dynamics is preferred.
  • Experience with prior authorization and payer processes is preferred.
  • Experience working with specialty treatment centers, integrated delivery networks, academic medical centers, or complex site-of-care models is preferred.
  • Experience supporting therapies requiring site certification, specialized administration, or coordinated care delivery models is highly desirable.

COMPASS Pathways develops psilocybin-based therapies for mental health, focusing on treating treatment-resistant depression (TRD). Its lead drug candidate, COMP360, is a high-purity psilocybin formulation given alongside psychological support from trained therapists. The treatment is delivered through a global Phase 3 program, aiming to establish a regulatory-approved therapy. Compared with other players, COMPASS emphasizes a standardized therapeutic model that pairs a pharmaceutical compound with guided psychotherapy and has the largest psilocybin Phase 3 program to date, supported by Breakthrough Therapy designation from the FDA. The company originated from a nonprofit idea, transformed into a for-profit entity to fund extensive trials, and is pursuing regulatory approval and eventual commercialization through licensing and partnerships. Its goal is to bring approved, evidence-based psilocybin treatments to patients with TRD and scale access through a commercial pathway.

Company Size

201-500

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2016

Get referred to Compass Pathways

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Compass reported $433.3 million cash on June 30, 2026, funding into 2028.
  • FDA granted rolling NDA review and a National Priority Voucher in April 2026.
  • Positive COMP006 data and VA collaboration strengthen launch credibility before first-half 2027.

What critics are saying

  • FDA rejection of the Q4 2026 NDA ends the 2027 launch and crushes Compass.
  • DEA rescheduling delays block commercialization even after FDA approval, pushing revenue past 2027.
  • Commercial adoption needs therapists, clinics, and payer coverage; weak reimbursement caps uptake.

What makes Compass Pathways unique

  • COMP360 is the first classic psychedelic with positive Phase 3 TRD data, July 2026.
  • Compass owns proprietary synthetic psilocybin and FDA Breakthrough Therapy designation for COMP360.
  • The VA PIVOT trial with veterans expands Compass into a uniquely credible federal channel.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-6%

2 year growth

-5%
Psychedelic Invest
Sep 2nd, 2026
Compass Pathways recognized as a 2026 Fierce 50 Breakthrough honoree.

Compass Pathways recognized as a 2026 Fierce 50 Breakthrough honoree. September 2, 2026 · Logan Lenz COMPASS Pathways Plc (CMPS) - LONDON & NEW YORK, September 02, 2026-Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.

Yahoo Finance
Aug 25th, 2026
Compass Pathways shares climb 25% in August ahead of Q4 FDA application filing for COMP360

Compass Pathways shares rose over 6% on Monday, contributing to a 25% gain in August, as the company prepares to complete its FDA application for COMP360, a synthetic psilocybin treatment for treatment-resistant depression. The firm expects to finish the full submission in the fourth quarter of this year, with a potential launch in the first half of 2027 if approved. The FDA previously granted COMP360 a special priority voucher, which could reduce the final review period to just one or two months. In early August, Compass reported a cash position of $433 million as of June, sufficient to fund operations into 2028. Two large late-stage studies demonstrated COMP360's quick-acting, long-lasting benefits. The company is also advancing a late-stage PTSD study whilst building commercial capabilities.

Psychedelic Invest
Aug 6th, 2026
Compass Pathways working with U.S. Department of veterans Affairs for investigational study of psilocybin.

Compass Pathways working with U.S. Department of veterans Affairs for investigational study of psilocybin. August 6, 2026 · Logan Lenz COMPASS Pathways Plc (CMPS) - LONDON & NEW YORK, August 06, 2026-Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumat

NovumPR
Aug 6th, 2026
Compass Pathways to participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026.

Compass Pathways to participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026. LONDON & NEW YORK-(BUSINESS WIRE)- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways NovumPR believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Its initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. NovumPR is leading the world's largest classic psychedelic clinical program in TRD, and building upon that robust foundation, NovumPR is executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Its goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing. Compass is headquartered in London, UK, with a U.S. office in New Jersey. NovumPR is driven by its purpose of unlocking pathways to be - opening futures filled with possibility. Together, NovumPR is on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Business Wire
Aug 5th, 2026
Compass Pathways reports H1 2026 results, on track for Q4 NDA filing for psilocybin TRD treatment

Compass Pathways announced second quarter and first half 2026 financial results as it progresses towards potential FDA approval of COMP360, its synthetic psilocybin treatment for treatment-resistant depression. The company reported cash and cash equivalents of $433.3 million as of 30 June 2026, up from $149.6 million at year-end 2025. Net loss was $162.6 million for the first half, compared with $56.3 million in the same period of 2025, primarily due to non-cash warrant fair value adjustments. Compass completed a rolling NDA submission to the FDA and expects to finalise remaining modules in Q4 2026. The company received a National Priority Voucher that could accelerate review time to one to two months. Commercial launch is expected in first half 2027, subject to FDA approval and DEA rescheduling. Current cash position is projected to fund operations into 2028.